Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a pilot study designed to determine a dose and schedule of Tucaresol that can be
administered to HIV-1 infected subjects on HAART (highly active antiretroviral therapy) with
viral suppression without occurrence of significant adverse events and that results in
significant changes in cell mediated immunity.